Should I buy or sell Amylyx Pharmaceuticals stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMLX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMLX, but not buy additional shares or sell existing shares. View AMLX analyst ratings or view top-rated stocks .

What is Amylyx Pharmaceuticals' stock price target for 2024?

8 Wall Street research analysts have issued 1-year target prices for Amylyx Pharmaceuticals' shares. Their AMLX share price targets range from $8.00 to $48.00. On average, they predict the company's share price to reach $32.67 in the next twelve months. This suggests a possible upside of 1,646.9% from the stock's current price. View analysts price targets for AMLX or view top-rated stocks among Wall Street analysts .

How have AMLX shares performed in 2024?

Amylyx Pharmaceuticals' stock was trading at $14.72 at the beginning of 2024. Since then, AMLX stock has decreased by 87.3% and is now trading at $1.87. View the best growth stocks for 2024 here .

When is Amylyx Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our AMLX earnings forecast .

How were Amylyx Pharmaceuticals' earnings last quarter?

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) released its earnings results on Thursday, February, 22nd. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.03. The company had revenue of $108.45 million for the quarter, compared to the consensus estimate of $106.40 million. Amylyx Pharmaceuticals had a trailing twelve-month return on equity of 12.39% and a net margin of 12.94%. During the same quarter in the previous year, the firm earned ($0.65) earnings per share.

What ETFs hold Amylyx Pharmaceuticals' stock?

ETFs with the largest weight of Amylyx Pharmaceuticals (NASDAQ:AMLX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) , SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) . iShares U.S. Pharmaceuticals ETF (IHE) .

When did Amylyx Pharmaceuticals IPO?

Amylyx Pharmaceuticals (AMLX) raised $190 million in an initial public offering on Friday, January 7th 2022. The company issued 10,000,000 shares at $18.00-$20.00 per share.

Who are Amylyx Pharmaceuticals' major shareholders?

Amylyx Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.17%) and Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include George M Milne Jr, Gina Mazzariello, Global Investors Lp Viking, James M Frates, Joshua B Cohen, Justin B Klee, Morningside Venture Investment and Patrick D Yeramian. View institutional ownership trends .

How do I buy shares of Amylyx Pharmaceuticals?

Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:AMLX

Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free AMLX Stock Alerts

$1.87

-0.11 (-5.56%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.85
▼
$2.02
50-Day Range: $1.87
▼
$19.57
52-Week Range: $1.85
▼
$31.28

Volume: 2.50 million shs
Average Volume: 2.86 million shs
Market Capitalization: $126.75 million

P/E Ratio: 2.67
Dividend Yield: N/A
Price Target: $32.67

Get Amylyx Pharmaceuticals alerts:

Amylyx Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Hold
2.25 Rating Score
Upside/Downside: 1,646.9% Upside
$32.67 Price Target
Short Interest: Bearish
12.63% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.00
Based on 2 Articles This Week
Insider Trading: Selling Shares
$193,098 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.01) to ($1.10) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.12 out of 5 stars

Medical Sector

278th out of 911 stocks

Pharmaceutical Preparations Industry

118th out of 419 stocks

4.1

Analyst's Opinion

Consensus Rating
Amylyx Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Amylyx Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.0

Short Interest

Percentage of Shares Shorted
12.63% of the float of Amylyx Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Amylyx Pharmaceuticals has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Amylyx Pharmaceuticals has recently increased by 18.07%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Amylyx Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Amylyx Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AMLX.

0.0

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 2 news articles for Amylyx Pharmaceuticals this week, compared to 6 articles on an average week.
Search Interest
Only 32 people have searched for AMLX on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.
MarketBeat Follows
Only 13 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -24% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Amylyx Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $193,098.00 in company stock.
Percentage Held by Insiders
11.80% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
95.84% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Amylyx Pharmaceuticals are expected to decrease in the coming year, from ($1.01) to ($1.10) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Amylyx Pharmaceuticals is 2.67, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.79.
Price to Earnings Ratio vs. Sector
The P/E ratio of Amylyx Pharmaceuticals is 2.67, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 191.80.
Price to Book Value per Share Ratio
Amylyx Pharmaceuticals has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX)

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

AMLX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

AMLX Stock News Headlines

April 17, 2024 | msn.com

Amylyx Pharmaceuticals (AMLX) Price Target Decreased by 17.36% to 4.34

April 15, 2024 | americanbankingnews.com

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Average Rating of "Hold" from Brokerages

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 12, 2024 | markets.businessinsider.com

Amylyx Pharmaceuticals: A Hold Rating Amidst Promising but Preliminary HELIOS Trial Results

April 11, 2024 | markets.businessinsider.com

Hold Rating on Amylyx Pharmaceuticals Amid Uncertainties in Drug Efficacy and Market Prospects

April 10, 2024 | msn.com

Amylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited Disorder

April 10, 2024 | finance.yahoo.com

Amylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome

April 10, 2024 | businesswire.com

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 9, 2024 | prnewswire.com

The Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLX

April 8, 2024 | markets.businessinsider.com

Optimistic Outlook for Amylyx Pharmaceuticals Inc with AMX0035’s Potential in Rare Diseases

April 8, 2024 | stockhouse.com

48 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

April 8, 2024 | businesswire.com

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)

April 8, 2024 | businesswire.com

Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024

April 8, 2024 | markets.businessinsider.com

Amylyx Pharmaceuticals Shifts Focus: Hold Recommendation Amidst R&D Pivot and Revenue Impact

April 8, 2024 | markets.businessinsider.com

Unveiling 6 Analyst Insights On Amylyx Pharma

April 8, 2024 | prnewswire.com

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) Shareholders

April 6, 2024 | finance.yahoo.com

Analysts Just Slashed Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) EPS Numbers

April 5, 2024 | markets.businessinsider.com

Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint - Hagens Berman

April 5, 2024 | prnewswire.com

AMLX Investors Have Opportunity to Lead Amylyx Pharmaceuticals, Inc. Securities Fraud Lawsuit

April 5, 2024 | prnewswire.com

Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AMLX

April 4, 2024 | markets.businessinsider.com

Amylyx Pharmaceuticals: Hold Rating Maintained Amidst Drug Discontinuation and Pipeline Developments

April 4, 2024 | prnewswire.com

AMLX FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX

April 4, 2024 | prnewswire.com

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - AMLX

April 4, 2024 | stockhouse.com

5-DAY DEADLINE ALERT: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

April 4, 2024 | bizjournals.com

Amylyx withdraws ALS drug after trial fail, slashes headcount

April 4, 2024 | bloomberg.com

Amylyx to Pull ALS Drug From Market After Failed Trial

See More Headlines

Receive AMLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/22/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:AMLX
CUSIP: N/A
CIK: 1658551
Web: amylyx.com
Phone: 617-682-0917
Fax: N/A
Employees: 384
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $32.67
High Stock Price Target: $48.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +1,646.9%
Consensus Rating: Hold
Rating Score (0-4): 2.25
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): $0.70
Trailing P/E Ratio: 2.67
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $49.27 million
Net Margins: 12.94%
Pretax Margin: 14.26%
Return on Equity: 12.39%
Return on Assets: 10.68%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.66
Quick Ratio: 5.20

Sales & Book Value

Annual Sales: $380.79 million
Price / Sales: 0.33
Cash Flow: $0.56 per share
Price / Cash Flow: 3.34
Book Value: $6.42 per share
Price / Book: 0.29

Miscellaneous

Outstanding Shares: 67,780,000
Free Float: 59,784,000
Market Cap: $126.75 million
Optionable: Optionable
Beta: -0.93

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Joshua B. Cohen (Age 32)
Co-Founder, Co-CEO & Director
Comp: $1M
Mr. Justin B. Klee (Age 33)
Co-Founder, Co-CEO & Director
Comp: $1M
Mr. James M. Frates M.B.A. (Age 57)
Chief Financial Officer
Comp: $695.12k
Ms. Gina M. Mazzariello (Age 53)
Chief Legal Officer & General Counsel
Comp: $794.83k
Mr. Tom Holmes
Chief Technical Operations Officer
Lindsey Allen
Head of Investor Relations & Communications
Ms. Shauna Horvath
Head of Global Marketing
Ms. Linda A. Arsenault
Chief Human Resources Officer
Mr. Chris Aiello
Head of Canada & GM
Mr. Keith White
Head of Global Market Access

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AMLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Amylyx Pharmaceuticals stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AMLX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMLX, but not buy additional shares or sell existing shares.
View AMLX analyst ratings or view top-rated stocks.
What is Amylyx Pharmaceuticals' stock price target for 2024?: 8 Wall Street research analysts have issued 1-year target prices for Amylyx Pharmaceuticals' shares. Their AMLX share price targets range from $8.00 to $48.00. On average, they predict the company's share price to reach $32.67 in the next twelve months. This suggests a possible upside of 1,646.9% from the stock's current price.
View analysts price targets for AMLX or view top-rated stocks among Wall Street analysts.
How have AMLX shares performed in 2024?: Amylyx Pharmaceuticals' stock was trading at $14.72 at the beginning of 2024. Since then, AMLX stock has decreased by 87.3% and is now trading at $1.87.
View the best growth stocks for 2024 here.
When is Amylyx Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our AMLX earnings forecast.
How were Amylyx Pharmaceuticals' earnings last quarter?: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) released its earnings results on Thursday, February, 22nd. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.03. The company had revenue of $108.45 million for the quarter, compared to the consensus estimate of $106.40 million. Amylyx Pharmaceuticals had a trailing twelve-month return on equity of 12.39% and a net margin of 12.94%. During the same quarter in the previous year, the firm earned ($0.65) earnings per share.

What ETFs hold Amylyx Pharmaceuticals' stock?: ETFs with the largest weight of Amylyx Pharmaceuticals (NASDAQ:AMLX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).
When did Amylyx Pharmaceuticals IPO?: Amylyx Pharmaceuticals (AMLX) raised $190 million in an initial public offering on Friday, January 7th 2022. The company issued 10,000,000 shares at $18.00-$20.00 per share.
Who are Amylyx Pharmaceuticals' major shareholders?: Amylyx Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Hennion & Walsh Asset Management Inc. (0.17%) and Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include George M Milne Jr, Gina Mazzariello, Global Investors Lp Viking, James M Frates, Joshua B Cohen, Justin B Klee, Morningside Venture Investment and Patrick D Yeramian.
View institutional ownership trends.
How do I buy shares of Amylyx Pharmaceuticals?: Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AMLX) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis

Amylyx Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX)

AMLX Stock Price History

AMLX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AMLX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™